No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:56:14.627Z. Latest historical point 2025-08-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Compass Therapeutics, Inc. (CMPX) stock was $0.96 as of Oct 5, 2026, 4:00 PM EDT, up 12.13% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -73.9% · 3-year avg -21.4%/yr · 5-year avg -22.8%/yr
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials.
Biotechnology · Boston, MA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.12
Revenue Est.
$229250.00
Last Quarter Results
EPS
$-0.13
vs Estimate
$-0.11
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CMPX | $172.99M | $0.96 | +12.13% | -73.87% | -22.79% | N/A | N/A |
| 2CHRS | $173.04M | $1.12 | -3.45% | -31.58% | -41.38% | -26.92% | vs CMPX |
| 3DTIL | $174.17M | $6.31 | +0.00% | +15.91% | -54.84% | N/A | vs CMPX |
| 4CUE | $176.96M | $24.36 | -4.73% | +11.33% | -42.42% | N/A | vs CMPX |
| 5CNTN | $179.70M | $2.33 | +3.56% | -19.85% | N/A | N/A | vs CMPX |
| 6ALXO | $162.82M | $1.21 | -0.82% | -44.34% | -56.07% | N/A | vs CMPX |
forward FY estimate
N/A
$0.00
vs Estimate
$-600000.00
Consensus Rating
Based on 11 analysts
Average Price Target
$5.45
+467.8% upside
Low
$1.00
Current
$0.96
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.16 | $-0.13 | $-0.11 | 9 |
| Quarter ending Dec 2026 | $-0.18 | $-0.14 | $-0.11 | 9 |
| Quarter ending Mar 2027 | $-0.13 | $-0.13 | $-0.13 | 6 |
| Quarter ending Jun 2027 | $-0.14 | $-0.14 | $-0.14 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.58 | $-0.50 | $-0.43 | 11 |
| FY 2027 | $-0.74 | $-0.56 | $-0.42 | 11 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $220435.00 | $229250.00 | $238065.00 | 13 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $1.59M | $1.59M | $1.59M | 6 |
| Quarter ending Jun 2027 | $255556.00 | $255556.00 | $255556.00 | 6 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $24.39M | $39.32M | $54.25M | 7 |
| FY 2027 | $1.78M | $10.15M | $18.52M | 10 |
